Prevalence and Incidence of Dementia in Patients With Non‐Overtly Functional Adrenal Tumours
Authors' conclusion
NOFAT was not associated with an increased risk of dementia.
Study context
- Population
- Patients diagnosed with NOFAT and controls, 2005–2019, Sweden; NOFAT: 59.4% women, median age 66 years; controls: 55.8% women, median age 66 years
- Participants
- 20,390 vs 125,392
- Exposure
- NOFAT vs controls
- NOFATn = 20,390
- Controlsn = 125,392reference
- Outcome
- Prevalence and incidence of dementia
Methodological detailsnational
- National
Main finding
As reported in the abstract
Dementia · median follow-up 4.9 years (IQR 2.2-8.2)
NOFAT vs ControlsEstimate (95% CI)
Lower prevalence with NOFAT
OR (prevalence) 0.58(0.50–0.68)
Dementia
aOR (prevalence) 0.47(0.40–0.56)
Incidence similar
HR (incidence) 1.05(0.97–1.15)
Dementia
aHR (incidence) 1.06(0.97–1.15)
Observational data: associations, not effects.
Secondary outcomes
Alzheimer's dementia (prevalence and incidence)
- Similar results to dementia; prevalence aOR
- 0.44 (0.34-0.57) (95% CI)
- Incidence aHR
- 0.94 (0.80-1.10) (95% CI)
Vascular dementia (prevalence and incidence)
- Similar results to dementia; prevalence OR
- 0.71 (0.52-0.94) (95% CI)
- Prevalence aOR
- 0.48 (0.35-0.64) (95% CI)
- Incidence HR
- 1.29 (1.08-1.53) (95% CI)
- Incidence aHR
- 1.13 (0.95-1.35) (95% CI)
Sensitivity analyses (gallbladder/biliary tract/pancreatic disease and acute appendicitis subgroups; 3- and 12-month malignancy-free survival)
- Similar results in the sensitivity analyses
Adrenalectomy
- Adrenalectomy did not change the results
Original publication
Prevalence and Incidence of Dementia in Patients With Non‐Overtly Functional Adrenal Tumours. Clin Endocrinol (Oxf). Published 25 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →